{"url":"https://lda.senate.gov/api/v1/filings/7a964508-e847-411a-9959-4ea41bbf3fc7/","filing_uuid":"7a964508-e847-411a-9959-4ea41bbf3fc7","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/7a964508-e847-411a-9959-4ea41bbf3fc7/print/","filing_document_content_type":"text/html","income":null,"expenses":"730000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Steve Giuli, Vice President of Government Affairs & Trade Relations","dt_posted":"2026-07-20T09:24:23-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2400 N. COMMERCE PARKWAY","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WESTON","registrant_state":"FL","registrant_zip":"33326","registrant":{"id":310973,"url":"https://lda.senate.gov/api/v1/registrants/310973/","house_registrant_id":38623,"name":"APOTEX CORP.","description":"Generic pharmaceutical manufacturer","address_1":"2400 N. COMMERCE PARKWAY","address_2":null,"address_3":null,"address_4":null,"city":"WESTON","state":"FL","state_display":"Florida","zip":"33326","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE GIULI","contact_telephone":"+1 954-384-8007","dt_updated":"2026-01-30T15:29:14.471073-05:00"},"client":{"id":183737,"url":"https://lda.senate.gov/api/v1/clients/183737/","client_id":12,"name":"APOTEX CORP.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"FL","state_display":"Florida","country":"US","country_display":"United States of America","ppb_state":"FL","ppb_state_display":"Florida","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2006-07-20"},"lobbying_activities":[{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Federal policy relating to providing federal funding to strengthen capabilities for domestic manufacturing of generic drugs and their ingredients; and Federal policy relating to amending Hatch-Waxman Act 180-day exclusivity eligibility to provide incentives for manufacturing generic pharmaceuticals and their ingredients in the United States and allied nations.","foreign_entity_issues":"Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.","lobbyists":[{"lobbyist":{"id":41476,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"GIULI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Federal policy relating to the review of the United States-Mexico-Canada trade agreement and the North American generic drug supply chain.","foreign_entity_issues":"Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.","lobbyists":[{"lobbyist":{"id":41476,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"GIULI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.","foreign_entity_issues":"Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.","lobbyists":[{"lobbyist":{"id":41476,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"GIULI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"HR 5526/S. 1954, the Biosimilar Red Tape Elimination Act, provisions relating to deeming a biosimilar interchangeable with its reference product immediately upon approval.","foreign_entity_issues":"Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.","lobbyists":[{"lobbyist":{"id":41476,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"GIULI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}